Evidence map›Paper›PMID 42432052›Full record

ArticleBreast cancer research and treatment2026

Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer.

Adhar Amritt, Abhilash Dagar, Adrija Ghosh, Arjun Maiti, Jaswin Raj, Sangeeta Hazarika, Ashish Datt Upadhyay, Jitendra K Meena, Abhinav Singhal, Aman Sharma and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Adhar AmrittDepartment of Radiation Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
Abhilash DagarDepartment of Radiation Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
Adrija GhoshDepartment of Radiation Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
Arjun MaitiDepartment of Radiation Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
Jaswin RajDepartment of Radiation Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
Sangeeta HazarikaDepartment of Radiation Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
Ashish Datt UpadhyayDepartment of Bio-Statistics, All India Institute of Medical Sciences, New Delhi, India.
Jitendra K MeenaDepartment of Preventive Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
Abhinav SinghalDepartment of Nuclear Medicine, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
Aman SharmaDepartment of Radiation Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
Jyoti SharmaDepartment of Surgical Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
Akash KumarDepartment of Medical Oncology, National Cancer Institute All India Institute of Medical Sciences, New Delhi, India.
Sandeep MathurDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Jyoutishman SaikiaDepartment of Surgical Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India.
Supriya MallickDepartment of Radiation Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India. drsupriyamallick@gmail.com.ORCID https://orcid.org/0000-0003-4228-5211

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStereotactic ablative body radiation (SABR), combined with systemic therapy (ST), is increasingly used to improve survival in oligometastatic breast cancer (OMBC).

methodsPatients with no brain or bone metastases on whole-body PET-CT received curative-intent local and systemic treatment, including SABR to metastatic site. Doses were: liver (45-50 Gy/5 fractions), peripheral lung (54 Gy/3fractions), central lung (60 Gy/8fractions), lymph nodes (30 Gy/3fractions), and peritoneal deposits (45 Gy/5fractions). Response was assessed at 3 months (RECIST v1.1); pain, gross tumour volume (GTV), planning target volume (PTV), and toxicity (CTCAE) were documented.

resultsFrom Dec 2021 to Mar 2025, 39 patients (42 sites; median age 47) were treated: liver (17), lung (14), nodes (5), other (6). At a median follow-up of 23.9 months, median PFS was 16.3 months (95% CI: 10.3-24.1); median OS was not reached; restricted mean OS for the cohort was 89.2 months. Twenty-eight patients were alive, 11 died, two were lost to follow-up. Subtypes included TNBC (36%) and HER2+ (33%), luminal B (23%). Univariate analysis showed older age, smaller PTV, and higher BED

conclusionCurative-intent treatment with SABR for visceral OMBC offers promising survival outcomes. Molecular subtyping may aid treatment selection. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Breast NeoplasmsRadiosurgeryAdultAgedCombined Modality TherapyFemaleHumansMiddle AgedNeoplasm MetastasisPositron Emission Tomography Computed TomographyTreatment OutcomeBreast cancerMetastasisOligo-metastasisStereotactic ablative body radiation (SABR)Visceral

Identifiers

PMID42432052

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.